About us

Lys Therapeutics, first-in-class biotherapies against neurological diseases

Meet our team

Dr. Manuel BLANC, PhD, MBA

Co-founder, Chief Executive Officer, President of the Strategic Committee

Philippe DUJARDIN

Co-founder, Chief Financial Officer, member of the Strategic Committee

Pr. Denis VIVIEN, PhD, PU-PH

Head of Science, President of the Scientific Advisory Board

Dr. Jean-Baptiste BERTRAND, PhD

Head of Clinical Operations

Dr. Nathalie DELETAGE, PhD

Senior Program Manager, Preclinical R&D

Dr. Flavie LESEPT, PhD

Program Manager, Preclinical R&D

Dr. Fanny POTZEHA, PhD

Project Manager, Preclinical R&D

Dr. François FOSSIEZ, PhD

Head of CMC

Werner KLINGER

Head of IT and data protection

Strategic Board

Dr. Pierre BELICHARD, PhD, MBA

Member of the Strategic Board

Dr. Pierre MORGON, PharmD, LL.M, MBA

Member of the Strategic Board

Philippe BISSAY, MBA

Member of the Strategic Board

Dr. Thibault HONEGGER, PhD

Member of the Strategic Board

Scientific Advisory Board

President of the SAB: Pr. Denis Vivien (PhD, PU-PH), France, co-inventor of Glunomab & expert of tPA, head of the Research Institute “Blood and Brain @ Caen-Normandie”

Pr. Diederik DIPPEL (MD, PhD), the Netherlands, neurologist, co-director of the Erasmus Medical Center, Rotterdam
 

Pr. Joan MONTANER (MD, PhD), Spain, neurologist, head of Neurovascular Research at the Vall d’Hebron Research Institute

Pr. Richard Macrez (MD, PhD), France, co-inventor of Glunomab, Professor and emergency physician, head of the Emergency Unit at Caen-Normandie Hospital

Dr. Désiré COLLEN (MD, PhD), Belgium, inventor of rtPA (alteplase) still the most effective drug for thrombolytic therapy of acute myocardial infarction and ischemic stroke

Pr. Yannick BÉJOT (MD, PhD), France, neurologist, head of Neurology at Dijon-Bourgogne hospital

Via BB@C Institute:  Pr. Eng Lo (MD, PhD), USA, neurologist, Professor of Neurology and Radiology, Harvard Medical School, and Research Staff, Massachusetts General Hospital

Via BB@C Institute: Pr. Martin Dichgans (MD, PhD), Germany, neurologist, Director of the Institute of Stroke and Dementia Research (Medical Center of the University of Munich), head of the World Stroke Organization

Science

A unique mechanism of action: a CNS drug which does not need to cross the blood-brain barrier

Glunozumab: a monoclonal antibody counteracting the neuroinflammatory and neurodegenerative processes implicated in the pathophysiology of neurological diseases by restoring the physiological function of the blood-brain barrier

Glunozumab monoclonal antibody: a groundbreaking mechanism of action targeting the blood-brain barrier dysfunctions

It is demonstrated that one endogenous protease called tissue plasminogen activator (tPA) is implicated in the pathophysiology of neurological diseases such as multiple sclerosis, Parkinson’s disease, stroke and other neurodegenerative disorders through its overexpression and binding to NMDA receptors (NMDAr) present on vascular endothelial cells and regulating the blood brain barrier (BBB) function / dysfunction. The overactivation of vascular NMDAr is triggering a strong increase of the permeability of the BBB allowing the transmigration of toxic immune cells to the brain parenchyma leading to neuroinflammation, ultimately causing neurodegeneration.

By blocking the tPA-NMDAr interaction inside the blood vessels, Glunozumab is restoring both NMDAr and blood-brain barrier physiological functioning (no perturbation of basal function), blocking both neuroinflammatory and neurodegenerative processes.

This unique mechanism of action implies that Glunozumab does not need to cross the BBB to act on the central nervous system, which is a distinctive feature for the treatment of neurological diseases.

A fully characterized mecanism of action:

Scientific publications of Lys Therapeutics and Pr. Denis Vivien et al. (Glunomab / Glunozumab):

Pipeline

Clinical development of Glunozumab

Newsroom

Career

We don’t have open positions at the moment, but stay tuned!

Contact us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Main offices: Lyon, France

56 rue Saint-Jean-De-Dieu

69007 LYON, France

Labs: Caen, France

Cyceron, Boulevard Henri Becquerel
Campus Jules Horowitz
14000 CAEN, France